MacroGenics GAAP EPS of -$0.32 misses by $0.28, revenue of $18.67M misses by $20.51M
MacroGenics reported Q3 GAAP EPS of -$0.32, missing estimates by $0.28. Revenue was $18.67M, down 64.8% year-over-year and missing expectations by $20.51M. The company's performance fell short of analysts' projections.
How this was made
The 30-second read
Why it matters
The earnings miss underscores execution risk and may trigger short-term volatility.
Market read
The report provides fresh quantitative data that can affect trading decisions for MGNX.
What to watch
Potential pipeline milestones or upcoming trial data could offset short-term earnings weakness.
Background
MacroGenics is a clinical-stage biotech focused on immuno-oncology.
Ticker impact
MacroGenics reported Q3 GAAP EPS of -$0.32 and revenue of $18.67M, both missing expectations.
likely pressure as the market prices in the earnings shortfall
The company posted a large revenue decline and a loss wider than expected, which typically depresses the stock.
Market effects
Biotech sector may see modest pullback as earnings disappointment adds to sector risk.
US biotech investors may adjust exposure.
Limited; impact confined to MacroGenics and similar small-cap biotech peers.
Counterpoint
If the miss is already priced in, the stock could stabilize and present a buying opportunity.
Key entities
- CompanyMacroGenics, Inc.
Issuer of the earnings report.
